Literature DB >> 2314008

Skin surface oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlusive disease.

A Creutzig1, L Caspary, K Alexander.   

Abstract

Prostaglandin E1 is offered as a new therapeutic agent in the treatment of severe peripheral arterial occlusive disease. Especially when treating patients with ulcers or gangrene, the oxygen tension of the skin should improve during PGE1 administration. The new technique of assessing skin surface oxygen pressure histograms allows study of the skin microcirculation in vivo. Oxygen histograms were determined on the forefeet of 19 patients with different degrees of disease and different occlusion levels before and during a single intraarterial infusion of PGE1 at a dosage of 1.5 ng/kg body weight/min. Only 9 patients showed improvement during the infusion period. Skin oxygen pressure was increased to a large extent only in patients assumed to suffer from diabetic microangiopathy. The effect of a long-term therapy with PGE1 on skin microcirculation remains to be settled.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2314008     DOI: 10.1007/bf01662716

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  10 in total

1.  [Results of operations for increasing blood supply (lumbar sympathectomy and arteriectomy) in chronic, spontaneous endarteritis obliterans of the extremities].

Authors:  R FONTAINE; R RIVEAUX; M KIM; R KIENY
Journal:  Rev Chir       Date:  1953 Jul-Oct

2.  Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions.

Authors:  N Parkhouse; P M Le Quesne
Journal:  N Engl J Med       Date:  1988-05-19       Impact factor: 91.245

3.  Metabolic effects of prostaglandin E1 on human skeletal muscle.

Authors:  H Stiegler; K Rett; M Wicklmayr; K Dietze; H Mehnert
Journal:  Vasa       Date:  1988       Impact factor: 1.961

4.  [Transcutaneous pO2 and laser Doppler flux in increasing doses of intraarterial and intravenously administered prostaglandin E1].

Authors:  A Creutzig; L Caspary; C Ranke; D Kiessling; J Wilkens; J Frölich; K Alexander
Journal:  Vasa       Date:  1987       Impact factor: 1.961

5.  Effects of intra-arterial prostaglandin E1 in patients with peripheral arterial occlusive disease.

Authors:  A Creutzig; H Creutzig; K Alexander
Journal:  Eur J Clin Invest       Date:  1986-12       Impact factor: 4.686

6.  Venous oxygenation in the diabetic neuropathic foot: evidence of arteriovenous shunting?

Authors:  A J Boulton; J H Scarpello; J D Ward
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

7.  Transcutaneous oxygen pressure measured at two different electrode core temperatures in healthy volunteers and patients with arterial occlusive disease.

Authors:  A Creutzig; D Dau; L Caspary; K Alexander
Journal:  Int J Microcirc Clin Exp       Date:  1987

8.  Skin surface oxygen pressure in healthy volunteers and patients with arterial occlusive disease.

Authors:  A Creutzig; L Caspary; K Alexander
Journal:  Int J Microcirc Clin Exp       Date:  1991-08

9.  [Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study].

Authors:  G Trübestein; M Ludwig; C Diehm; J D Gruss; S Horsch
Journal:  Dtsch Med Wochenschr       Date:  1987-06-12       Impact factor: 0.628

10.  Blood flow in the foot, polyneuropathy and foot ulceration in diabetes mellitus.

Authors:  D O Corbin; R J Young; D C Morrison; P Hoskins; W N McDicken; E Housley; B F Clarke
Journal:  Diabetologia       Date:  1987-07       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.